A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1335
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab ; day:17 ; month:4 ; year:2021 ; pages:1-10
Journal of cancer research and clinical oncology ; (17.4.2021), 1-10
- Creator
-
Hummel, Matthew
Bosje, Tjerk
Shaw, Andrew
Liu, Mark Shiyao
Barve, Abhijit
Kothekar, Mudgal
Socinski, Mark A.
Waller, Cornelius
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-021-03628-0
- URN
-
urn:nbn:de:101:1-2021060512001928249244
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hummel, Matthew
- Bosje, Tjerk
- Shaw, Andrew
- Liu, Mark Shiyao
- Barve, Abhijit
- Kothekar, Mudgal
- Socinski, Mark A.
- Waller, Cornelius
- SpringerLink (Online service)
Other Objects (12)
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Dopplersonographische Messung der Blutflussgeschwindigkeit in der Arteria mesenterica superior
Mobilisierung und Purging autologer Blutstammzellen als Voraussetzung der Hochdosis-Chemotherapie bei malignen Erkrankungen unter besonderer Berücksichtigung der chronischen myeloischen Leukämie
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management
Chemotherapie und febrile Neutropenie : Probleme und Konzepte
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Dopplersonographische Messung der Blutflussgeschwindigkeit in der Arteria mesenterica superior
Mobilisierung und Purging autologer Blutstammzellen als Voraussetzung der Hochdosis-Chemotherapie bei malignen Erkrankungen unter besonderer Berücksichtigung der chronischen myeloischen Leukämie
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management
Chemotherapie und febrile Neutropenie : Probleme und Konzepte
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Dopplersonographische Messung der Blutflussgeschwindigkeit in der Arteria mesenterica superior
Mobilisierung und Purging autologer Blutstammzellen als Voraussetzung der Hochdosis-Chemotherapie bei malignen Erkrankungen unter besonderer Berücksichtigung der chronischen myeloischen Leukämie
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management